Patented Universal Tumor-Targeting Drug Delivery Platform Co.
Patented Tumor-Targeting Drug Delivery Platform in Irvine, CA
On NextCompany since September 10, 2026 (35 days)
Irvine, CA
Business overview
This Irvine, CA company develops a patented drug-delivery platform targeting solid-tumor necrosis. The platform uses lipid nanoparticles coated with human-sourced antinuclear antibodies. The company reports a successful Ewing’s Sarcoma mouse proof-of-concept study at Children’s Hospital. The FDA granted Orphan Drug Designation for two lead formulations.
The company seeks supportive capital partners to advance into clinical studies. It anticipates pharmaceutical licensing agreements covering existing and developing drugs. The asking price is $20,000,000. The transaction includes a transition team.
Who is a good fit for this business
- Capital partners seeking to support a drug-delivery platform’s advancement into clinical studies.
- Pharmaceutical companies seeking licensing opportunities for existing and developing drugs.
Details
- Reason for selling
- Seeking supportive capital partners to take to the next level(s).
Frequently Asked Questions
The company’s patented platform targets solid-tumor necrosis. It uses lipid nanoparticles coated with human-sourced antinuclear antibodies.
The company reports a successful Ewing’s Sarcoma mouse proof-of-concept study at Children’s Hospital. The FDA granted Orphan Drug Designation for two lead formulations.
The listing carries a $20,000,000 asking price. The company seeks supportive capital partners to advance into clinical studies.
The company anticipates licensing agreements with pharmaceutical companies. Its plans cover both existing and developing drugs.
The transaction includes a transition team. The seller conditions financing on an acceptable price and deal structure.